The feasibility study of cisplatin-containing combination chemotherapy with a short hydration regimen for advanced gastric cancer

The feasibility study of cisplatin-containing combination chemotherapy with a short hydration regimen for advanced gastric cancer - The feasibility study of cisplatin-containing combination chemotherapy with a short hydration regimen for advanced gastric cancer

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009499

Enrollment

Registered

2012-12-07

Start date

2012-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced or recurrent gastric cancer

Interventions

Cisplatin-containing combination chemotherapy with a short hydration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.ECOG Performance status(PS) of 0-2 2.Patients who have not been treated systemic chemotherapy within the past 5 years 3.Patients who is possible of ingestion 4.The estimated Ccr of 60mL/min or higher 5.Written informed consent

Exclusion criteria

Exclusion criteria: 1.with severe diseases (hepatic failure, pulmonary disease, heart failure, hematologic disorder) 2.with uncontrollable DM 3.with active double cancer 4.pregnant and/or nursing women 5.symptomatic psychological disease 6.HBs-Ag positive and/or HCV-Ab positive 7.with active infection 8.any other patient whom the physician in charge of the study judges to be unsuitable

Design outcomes

Primary

Measure	Time frame
Incidence of nephrotoxicity	—

Secondary

Measure	Time frame
Incidence of adverse event other than nephrotoxicity, response rate, progression free survival, Cisplatin treatment completion rate	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026